Lakefront Biotherapeutics NV (LKFT)
NASDAQ: LKFT · Real-Time Price · USD
27.73
0.00 (0.00%)
At close: May 8, 2026, 4:00 PM EDT
28.59
+0.86 (3.10%)
After-hours: May 8, 2026, 4:00 PM EDT
LKFT Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 1,044 | 1,112 | 275.65 | 239.72 | 241.25 | 234.38 |
Revenue | 1,044 | 1,112 | 275.65 | 239.72 | 241.25 | 234.38 |
Revenue Growth (YoY) | 262.17% | 303.50% | 14.99% | -0.63% | 2.93% | -50.97% |
Cost of Revenue | 480.23 | 489.16 | 370.32 | 241.29 | 269.8 | 320.5 |
Gross Profit | 563.53 | 623.09 | -94.67 | -1.57 | -28.55 | -86.12 |
Selling, General & Admin | 133.01 | 141.31 | 133.2 | 130.82 | 138.64 | 131.52 |
Research & Development | -151.79 | - | - | - | - | - |
Other Operating Expenses | -47.98 | -53.49 | -40.77 | -47.27 | -36.13 | -46.07 |
Operating Expenses | -66.76 | 87.81 | 92.42 | 83.54 | 102.51 | 85.45 |
Operating Income | 630.28 | 535.28 | -187.1 | -85.11 | -131.06 | -171.57 |
Interest Expense | -0.39 | -1.03 | -0.91 | -1.77 | -6.88 | -11.59 |
Interest & Investment Income | 46.34 | 46.34 | 89.38 | 79.29 | 18.09 | 2.87 |
Currency Exchange Gain (Loss) | -45.01 | -45.01 | 22.05 | -21.66 | 44.38 | 56.66 |
Other Non Operating Income (Expenses) | 97.3 | 22.63 | 1 | 0.13 | -2.32 | 2.39 |
EBT Excluding Unusual Items | 728.52 | 558.2 | -75.58 | -29.12 | -77.78 | -121.25 |
Merger & Restructuring Charges | -228.11 | -228.11 | - | - | - | - |
Gain (Loss) on Sale of Investments | -17.09 | -17.09 | 73.74 | 37.9 | 6.93 | 1.84 |
Asset Writedown | -15.28 | -15.28 | -1.24 | - | - | - |
Other Unusual Items | 3.15 | 3.15 | - | -3.15 | - | - |
Pretax Income | 471.19 | 300.87 | -3.09 | 5.63 | -70.85 | -119.4 |
Income Tax Expense | -16.74 | -18.62 | -1.8 | 9.61 | 0.57 | 1.39 |
Earnings From Continuing Operations | 487.93 | 319.49 | -1.28 | -3.99 | -71.42 | -120.79 |
Earnings From Discontinued Operations | 0.85 | 1.39 | 75.36 | 215.69 | -146.57 | 17.56 |
Net Income | 488.78 | 320.88 | 74.08 | 211.7 | -217.99 | -103.23 |
Net Income to Common | 488.78 | 320.88 | 74.08 | 211.7 | -217.99 | -103.23 |
Net Income Growth | - | 333.15% | -65.01% | - | - | - |
Shares Outstanding (Basic) | 66 | 66 | 66 | 66 | 66 | 66 |
Shares Outstanding (Diluted) | 66 | 66 | 66 | 66 | 66 | 66 |
Shares Change (YoY) | 0.03% | -0.06% | 0.01% | 0.36% | 0.30% | 0.65% |
EPS (Basic) | 7.42 | 4.87 | 1.12 | 3.21 | -3.32 | -1.58 |
EPS (Diluted) | 7.42 | 4.87 | 1.12 | 3.21 | -3.32 | -1.58 |
EPS Growth | - | 333.66% | -65.05% | - | - | - |
Free Cash Flow | -310.33 | -271.16 | -336.75 | -424.68 | -527.93 | -558.03 |
Free Cash Flow Per Share | -4.71 | -4.12 | -5.11 | -6.44 | -8.04 | -8.52 |
Gross Margin | 53.99% | 56.02% | -34.34% | -0.66% | -11.83% | -36.74% |
Operating Margin | 60.39% | 48.13% | -67.87% | -35.50% | -54.32% | -73.20% |
Profit Margin | 46.83% | 28.85% | 26.88% | 88.31% | -90.36% | -44.04% |
Free Cash Flow Margin | -29.73% | -24.38% | -122.16% | -177.15% | -218.83% | -238.09% |
EBITDA | 662.96 | 568.17 | -153.32 | -41.47 | -65.49 | -163.26 |
EBITDA Margin | 63.52% | 51.08% | -55.62% | -17.30% | -27.15% | -69.65% |
D&A For EBITDA | 32.67 | 32.89 | 33.78 | 43.64 | 65.57 | 8.31 |
EBIT | 630.28 | 535.28 | -187.1 | -85.11 | -131.06 | -171.57 |
EBIT Margin | 60.39% | 48.13% | -67.87% | -35.50% | -54.32% | -73.20% |
Effective Tax Rate | - | - | - | 170.90% | - | - |
Revenue as Reported | 1,044 | 1,112 | 275.65 | 239.72 | 241.25 | 234.38 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.